Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Lung Cancer patients with non-small cell histology and stage IV disease
candidate for erlotinib treatment as first/ second/ third line of treatment
You may not be if
pregnancy
severe dyspnoea
Clareo Health | Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
